Urovant Sciences, Inc

5281 California Ave, Suite #100
United States

Tel: +1 949 226 6029

Email: info@urovant.com

Show jobs for this employer

About Urovant Sciences, Inc

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant's lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit www.urovant.com

Stock Symbol: UROV

Stock Exchange: NASDAQ

LinkedIn  Twitter

83 articles with Urovant Sciences, Inc